Chinese Firms' Delisting Uncertainty Lifted For Now But Clock Ticking
New US Deal Seen As Just First Step
A new bilateral agreement between securities regulatory authorities in the US and China is being seen as a welcome first step in addressing issues around US inspections of auditors of US-listed Chinese firms, but implementation will be key.
You may also be interested in...
BeiGene/Novartis's Tislelizumab Faces US Delay Over China Inspection Challenges
An inability to conduct manufacturing field inspections in China due to strict local COVID-19 policies is cited as the only reason for the delay for the anti-PD-1 drug, for which the timescale for resolution is currently unclear.
Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking
China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.
COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says
CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.